EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Therapeutic Perspectives for Inflammation and Senescence in Osteoarthritis Using Mesenchymal Stem Cells, Mesenchymal Stem Cell-Derived Extracellular Vesicles and Senolytic Agents

Michael G Rizzo iD, Thomas M Best, Johnny Huard, Marc Philippon, Francis Hornicek, Zhenfeng Duan, Anthony J Griswold iD, Lee D Kaplan, Joshua M Hare iD, Dimitrios Kouroupis iD

Cells · 2023-05-18 · 12 (10) · 1421

DOI: 10.3390/cells12101421 ↗

At a glance

Übersichtsarbeit in Cells, published online on 2023-05-18. Written by Michael G Rizzo and 9 co-authors. Institution: Department of Orthopedics, UHealth Sports Medicine Institute, University of Miami Miller School of Medicine, Miami, FL 33146, USA. Major MEDLINE topics: Extracellular Vesicles, Osteoarthritis, Mesenchymal Stem Cells. Cited 51 times so far (Crossref); 229 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIH HHS, NIAMS NIH HHS, National Institutes of Health.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Osteoarthritis (OA) is the most common cause of disability worldwide among the elderly. Alarmingly, the incidence of OA in individuals less than 40 years of age is rising, likely due to the increase in obesity and post-traumatic osteoarthritis (PTOA). In recent years, due to a better understanding of the underlying pathophysiology of OA, several potential therapeutic approaches targeting specific molecular pathways have been identified. In particular, the role of inflammation and the immune system has been increasingly recognized as important in a variety of musculoskeletal diseases, including OA. Similarly, higher levels of host cellular senescence, characterized by cessation of cell division and the secretion of a senescence-associated secretory phenotype (SASP) within the local tissue microenvironments, have also been linked to OA and its progression. New advances in the field, including stem cell therapies and senolytics, are emerging with the goal of slowing disease progression. Mesenchymal stem/stromal cells (MSCs) are a subset of multipotent adult stem cells that have demonstrated the potential to modulate unchecked inflammation, reverse fibrosis, attenuate pain, and potentially treat patients with OA. Numerous studies have demonstrated the potential of MSC extracellular vesicles (EVs) as cell-free treatments that comply with FDA regulations. EVs, including exosomes and microvesicles, are released by numerous cell types and are increasingly recognized as playing a critical role in cell–cell communication in age-related diseases, including OA. Treatment strategies for OA are being developed that target senescent cells and the paracrine and autocrine secretions of SASP. This article highlights the encouraging potential for MSC or MSC-derived products alone or in combination with senolytics to control patient symptoms and potentially mitigate the progression of OA. We will also explore the application of genomic principles to the study of OA and the potential for the discovery of OA phenotypes that can motivate more precise patient-driven treatments.

Subjects

MeSH terms (MEDLINE)

Extracellular VesiclesOsteoarthritisMesenchymal Stem CellsHumansSenotherapeuticsInflammation

Author keywords

cell-based therapiescellular senescenceextracellular vesiclesinflammationmesenchymal stem/stromal cellsosteoarthritissenescence-associated secretory phenotypesenolytics

Substances

Senotherapeutics

Authors and institutions

  • Department of Orthopedics, UHealth Sports Medicine Institute, University of Miami Miller School of Medicine, Miami, FL 33146, USA.
  • Center for Regenerative and Personalized Medicine (CRPM), Steadman Philippon Research Institute, Vail, CO 81657, USA.
  • Department of Orthopedics, Sarcoma Biology Laboratory, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
  • John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
  • Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
  • Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.

ORCID profiles: Michael G Rizzo, Anthony J Griswold, Joshua M Hare, Dimitrios Kouroupis

Funding

  • NIH HHS
  • NIAMS NIH HHS
  • National Institutes of Health

Cite

APA

Rizzo, M. G., Best, T. M., Huard, J., Philippon, M., Hornicek, F., Duan, Z., Griswold, A. J., Kaplan, L. D., Hare, J. M., & Kouroupis, D. (2023). Therapeutic Perspectives for Inflammation and Senescence in Osteoarthritis Using Mesenchymal Stem Cells, Mesenchymal Stem Cell-Derived Extracellular Vesicles and Senolytic Agents. Cells, 12(10), 1421. https://doi.org/10.3390/cells12101421

Vancouver

Rizzo MG, Best TM, Huard J, Philippon M, Hornicek F, Duan Z, et al. Therapeutic Perspectives for Inflammation and Senescence in Osteoarthritis Using Mesenchymal Stem Cells, Mesenchymal Stem Cell-Derived Extracellular Vesicles and Senolytic Agents. Cells. 2023;12(10):1421. doi:10.3390/cells12101421

BibTeX
@article{Rizzo2023,
  author = {Rizzo, Michael G and Best, Thomas M and Huard, Johnny and Philippon, Marc and Hornicek, Francis and Duan, Zhenfeng and Griswold, Anthony J and Kaplan, Lee D and Hare, Joshua M and Kouroupis, Dimitrios},
  title = {Therapeutic Perspectives for Inflammation and Senescence in Osteoarthritis Using Mesenchymal Stem Cells, Mesenchymal Stem Cell-Derived Extracellular Vesicles and Senolytic Agents},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {10},
  pages = {1421},
  doi = {10.3390/cells12101421}
}
Start for free →